CSL Community

ASX:CSL Community

2 Narratives written by author
4 Comments on narratives written by author
284 Fair Values set on narratives written by author

RA

Community Contributor

CSL is undervalued in High Tax Scenario

CSL Limited: Fair Value Assessment Amidst Evolving US Tariff Scenarios Executive Summary This report provides an assessment of the fair value of CSL Limited (CSL) under various potential United States (US) tariff scenarios. CSL, a global biotechnology leader with significant operations in plasma therapies (CSL Behring), influenza vaccines (CSL Seqirus), and iron/nephrology treatments (CSL Vifor), faces potential impacts from evolving US trade policies.

AU$263.33

FV

8.1% undervalued

6.00%

Revenue growth p.a.

3

0

32

10 days ago

AN

AnalystConsensusTarget

Consensus Narrative from 17 Analysts

Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position

Key Takeaways Advancements in plasma collection and operational efficiencies are set to reduce costs and improve CSL Behring's margins, potentially boosting overall earnings. Product rollouts and expanded market approvals, especially in HAE therapy, aim to drive revenue growth and offset vaccine sector challenges.

AU$311.94

FV

22.5% undervalued

6.91%

Revenue growth p.a.

2

0

93

1 day ago